Terms: = Germ cell tumor AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
3120 results:
1. braf-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to treatment.
Bravo-Garzón MA; Bornstein-Quevedo L; Camargo VP; Sanku G; Jansen AM; Macedo MP; Rico-Restrepo M; Chacón M
Cancer Control; 2024; 31():10732748241251572. PubMed ID: 38751033
[TBL] [Abstract] [Full Text] [Related]
2. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
[TBL] [Abstract] [Full Text] [Related]
3. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract] [Full Text] [Related]
4. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (germELATOX-A): the doctors' perspective.
Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
[TBL] [Abstract] [Full Text] [Related]
5. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract] [Full Text] [Related]
6. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.
Schaff LR; Ioannou M; Geurts M; van den Bent MJ; Mellinghoff IK; Schreck KC
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431450. PubMed ID: 38723228
[TBL] [Abstract] [Full Text] [Related]
7. Genetics-guided therapy in neuroendocrine carcinoma: response to braf- and MEK-inhibitors.
Falkman L; Sundin A; Skogseid B; Botling J; Bernardo Y; Wallin G; Zhang L; Welin S; Lase I; Mollazadegan K; Crona J
Ups J Med Sci; 2024; 129():. PubMed ID: 38716076
[TBL] [Abstract] [Full Text] [Related]
8. [Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.].
Cerro M; Maccallini MT; Russillo M
Recenti Prog Med; 2024 May; 115(5):13e-16e. PubMed ID: 38708541
[TBL] [Abstract] [Full Text] [Related]
9. [Advanced melanoma with low-burden and low-risk disease: a clinical case.].
Bersanelli M
Recenti Prog Med; 2024 May; 115(5):7e-12e. PubMed ID: 38708540
[TBL] [Abstract] [Full Text] [Related]
10. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
11. Editorial: First Regulatory Approval for Adoptive cell Therapy with Autologous tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).
Parums DV
Med Sci Monit; 2024 May; 30():e944927. PubMed ID: 38689550
[TBL] [Abstract] [Full Text] [Related]
12. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
13. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
14. Lifileucel: First Approval.
Keam SJ
Mol Diagn Ther; 2024 May; 28(3):339-344. PubMed ID: 38625642
[TBL] [Abstract] [Full Text] [Related]
15. Overcoming braf and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
[TBL] [Abstract] [Full Text] [Related]
16. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced braf-mutant melanoma.
Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
[TBL] [Abstract] [Full Text] [Related]
17. Development and in-depth characterization of brafi-resistant melanoma cell lines in vitro and in vivo.
Saraswat A; Patel K
Exp Cell Res; 2024 May; 438(1):114033. PubMed ID: 38593916
[TBL] [Abstract] [Full Text] [Related]
18. Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Whitman ED; Totev TI; Jiang S; da Costa WL; Grebennik D; Wang H; Boca AE; Ayyagari R
BMC Cancer; 2024 Mar; 24(1):389. PubMed ID: 38539148
[TBL] [Abstract] [Full Text] [Related]
19. Investigational Approaches for treatment of Melanoma Patients Progressing After Standard of Care.
Fletcher KA; Johnson DB
Cancer J; 2024 Mar-Apr 01; 30(2):126-131. PubMed ID: 38527267
[TBL] [Abstract] [Full Text] [Related]
20. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract] [Full Text] [Related]
[Next]
